Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Matzkin

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Clinical Endocrinology|November 1, 1992
Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolismH Matzkin, J Chen, Y Weisman, et al.
Endocrinology|April 1, 1996
Functional melatonin receptors in human prostate epithelial cellsE Gilad, M Laudon, H Matzkin, et al.
British Journal of Urology|August 1, 1993
How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia?H Matzkin, R van der Zwaag, Y Chen, et al.
The Prostate|October 3, 2001
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activityA Rimler, Z Culig, G Levy-Rimler, et al.
The Journal of Urology|January 13, 2006
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once dailyR Hartung, H Matzkin, A Alcaraz, et al.
Cancer|August 15, 1993
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogenH Matzkin, M S Soloway, P F Schellhammer, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Clinical Endocrinology|November 1, 1992
Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolismH Matzkin, J Chen, Y Weisman, et al.
Endocrinology|April 1, 1996
Functional melatonin receptors in human prostate epithelial cellsE Gilad, M Laudon, H Matzkin, et al.
British Journal of Urology|August 1, 1993
How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia?H Matzkin, R van der Zwaag, Y Chen, et al.
The Prostate|October 3, 2001
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activityA Rimler, Z Culig, G Levy-Rimler, et al.
The Journal of Urology|January 13, 2006
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once dailyR Hartung, H Matzkin, A Alcaraz, et al.
Cancer|August 15, 1993
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogenH Matzkin, M S Soloway, P F Schellhammer, et al.
Pageof 11